Caduet, the ARB+Statin drug, keeps its indisputable position at the top while Hanmi and Daewoong are chasing
It is known that Pfizer’s Caduet has kept its position at the top in the ARB+Statin drug market, representing hypertension+hyperlipidemia complexes. Then, it is followed by other last movers, such as Hanmi Pharm and Daewoong Pharmaceutical.
Caduet (atorvastatin and amlodipine), the first hyperte...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
